BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24190862)

  • 1. Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
    Cai Y; Cai T; Chen Y
    J Cell Biochem; 2014 Apr; 115(4):625-31. PubMed ID: 24190862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis.
    Xi Y; Chen Y
    Cancer Lett; 2014 Oct; 353(1):8-16. PubMed ID: 25042867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt signaling in osteosarcoma.
    Lin CH; Ji T; Chen CF; Hoang BH
    Adv Exp Med Biol; 2014; 804():33-45. PubMed ID: 24924167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulated lnc-SNHG1 contributes to osteosarcoma progression through sequestration of miR-577 and activation of WNT2B/Wnt/β-catenin pathway.
    Jiang Z; Jiang C; Fang J
    Biochem Biophys Res Commun; 2018 Jan; 495(1):238-245. PubMed ID: 29108989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt pathway, an essential role in bone regeneration.
    Chen Y; Alman BA
    J Cell Biochem; 2009 Feb; 106(3):353-62. PubMed ID: 19127541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.
    Cai Y; Mohseny AB; Karperien M; Hogendoorn PC; Zhou G; Cleton-Jansen AM
    J Pathol; 2010 Jan; 220(1):24-33. PubMed ID: 19882675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
    Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells.
    Dieudonné FX; Marion A; Haÿ E; Marie PJ; Modrowski D
    Cancer Res; 2010 Jul; 70(13):5399-408. PubMed ID: 20530678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionalized curcumin analogs as potent modulators of the Wnt/β-catenin signaling pathway.
    Leow PC; Bahety P; Boon CP; Lee CY; Tan KL; Yang T; Ee PL
    Eur J Med Chem; 2014 Jan; 71():67-80. PubMed ID: 24275249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/β-Catenin Signaling Activates Expression of the Bone-Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types.
    Vega OA; Lucero CMJ; Araya HF; Jerez S; Tapia JC; Antonelli M; Salazar-Onfray F; Las Heras F; Thaler R; Riester SM; Stein GS; van Wijnen AJ; Galindo MA
    J Cell Biochem; 2017 Nov; 118(11):3662-3674. PubMed ID: 28370561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.
    Ramachandran I; Thavathiru E; Ramalingam S; Natarajan G; Mills WK; Benbrook DM; Zuna R; Lightfoot S; Reis A; Anant S; Queimado L
    Oncogene; 2012 May; 31(22):2725-37. PubMed ID: 22002305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant activation of Wnt/β-catenin signaling pathway contributes to the sequential progression of DMBA-induced HBP carcinomas.
    Vidya Priyadarsini R; Senthil Murugan R; Nagini S
    Oral Oncol; 2012 Jan; 48(1):33-9. PubMed ID: 21924667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt Signaling in Osteosarcoma.
    Singla A; Wang J; Yang R; Geller DS; Loeb DM; Hoang BH
    Adv Exp Med Biol; 2020; 1258():125-139. PubMed ID: 32767238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCAR2 promotes a malignant phenotype of osteosarcoma through Wnt/β-catenin-dependent transcriptional activation of SPARC.
    Chen L; Zhou SJ; Xu Y; Liao QM; Zou YS; Pei H
    Biochem Biophys Res Commun; 2021 Nov; 580():67-73. PubMed ID: 34624572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
    Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors.
    Pridgeon MG; Grohar PJ; Steensma MR; Williams BO
    Curr Osteoporos Rep; 2017 Aug; 15(4):239-246. PubMed ID: 28647886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma.
    Ji T; Guo Y; Kim K; McQueen P; Ghaffar S; Christ A; Lin C; Eskander R; Zi X; Hoang BH
    Mol Cancer; 2015 Apr; 14():86. PubMed ID: 25890345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The canonical Wnt-beta-catenin pathway in development and chemotherapy of osteosarcoma.
    Li C; Shi X; Zhou G; Liu X; Wu S; Zhao J
    Front Biosci (Landmark Ed); 2013 Jun; 18(4):1384-91. PubMed ID: 23747891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt inhibitory factor-1 functions as a tumor suppressor through modulating Wnt/β-catenin signaling in neuroblastoma.
    Zhang J; Zhou B; Liu Y; Chen K; Bao P; Wang Y; Wang J; Zhou Z; Sun X; Li Y
    Cancer Lett; 2014 Jun; 348(1-2):12-9. PubMed ID: 24561119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Wnt/β-catenin pathway in ovarian cancer: a review.
    Arend RC; Londoño-Joshi AI; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2013 Dec; 131(3):772-9. PubMed ID: 24125749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.